Form D · Biotechnology

Envisia Therapeutics, Inc.

Morrisville, NC · CIK 0001655970

Offering snapshot reported Mar 17, 2016 · SEC filing

Reported sold
$10.1M
Offering amount: $16.5M
Investors reported
9
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Mar 11, 2016
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Mar 17, 2016Initial$10,117,521No comparison9SEC filing
Oct 19, 2015Initial$4,600,000No comparison5SEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired, Other
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-259444
Total amount sold includes the value of cancelled indebtedness formerly held by certain purchasers in the aggregate principal amount of $4,944,000.
Offer and sale of Series A Preferred Stock and Warrants to purchase Series A Preferred Stock, and the underlying shares of common stock issuable upon conversion thereof.

Source: Form D, filed Mar 17, 2016. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Stephen Bloch Director
Neal Fowler Director
Adrienne Graves Director
Eric Linsley Executive
Ed Mathers Director
Gary Phillips Director
Seth Rudnick Director
William Yelle Director
Ben Yerxa Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
419 Davis Drive Suite 100
Morrisville, NC, 27560